RNase L activators and antisense oligonucleotides effective to treat telomerase-expressing malignancies
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Oct 22, 2002
Grant Date -
Jul 12, 2001
app pub date -
Feb 3, 1998
filing date -
Apr 21, 1997
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
The present invention relates to chimeric molecules comprising an oligonucleotide complementary to a region of the ribonucleotide component of telomerase attached to an activator of RNase L ('activator-antisense complex') which specifically cleaves the ribonucleotide portion of a telomerase enzyme. The present invention relates to methods of inhibiting telomerase enzymatic activity with activator-antisense complexes targeted to the RNA component of telomerase. The present invention further relates to methods of treating malignant neoplastic disease, wherein the malignant cells contain a telomerase activity that is necessary for the growth of the malignant cells.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully